Report by
Thank you for your report!
IMPORTANT - YOUR REPORT IS QUEUED - IT MAY TAKE UP TO 12 HOURS FOR YOUR REPORT TO SHOW ON OUR HOME PAGE (IF NOT OPTED AS PRIVATE)
If your report is poison related call
1-800-222-1222
for a free consultation with a live medical poisoning expert
Visit our learn pages for more helpful information or, email us:
support@safelyhq.com
Goodbye! and best wishes in your recovery
Peet's Coffee
Updated: August 17, 2021 12:00 PM
Covid-19 OSHA Complaint, Peet's Coffee, Inc., 5100 Main St., DOWNERS GROVE, IL, 60515, USA
1 month ago
Social distancing is not being enforced behind the bar, where employees prepare beverages for customers. OSHA Applicable Standard: 5(a)(1) of the OSH Act. Employees who have had contact with a COVID positive person are not asked to quarantine. OSHA Applicable Standard: 5(a)(1) of the OSH Act.
Source:... See More Osha.gov | Receipt Date: 2021-04-14 See Less
The employer failed to disinfect surfaces after twelve employees were excluded from the workplace due to COVID-19 infections. T8 CCR 3205(c)(8)(C)
Alleged Hazards: 1, Employees Exposed: 12
Source: Osha.gov | Receipt Date: 2021-01-26 See Less
An employee at Peet's Coffee located on Broadway in Oakland recently tested positive for Covid-19
Source: zackhaber.medium.com See Less
1. Employees preparing foods/drinks and those interacting with customers are not provided with adequate and readily available personal protective equipment (PPE) to minimize risk of exposure to Covid-19.
Possible Applicable OSHA: Section 5(a)(1) of the OSH Act.
Source: Osha.gov | Receipt Date: 2020-07-31 See Less
1. The employer is not following CDC guidelines regarding to the use of facemasks or face coverings, only one reusable cloth mask was provided by the company to each employee.
Applicable OSHA standard(s): Section 5(a)(1) General Duty Clause of the Occupational Safety and Health Act of 1970,... See More 1910.132
2. Employees are required to perform duties behind the counter and bar area that becomes crowded at times. The close quarters in the work area require employees to be within 6 feet of each other. The employer is not following CDC guidelines regarding maintaining 6 feet of social distancing.
Applicable OSHA standard(s): Section 5(a)(1) General Duty Clause of the Occupational Safety and Health Act of 1970
3. The employer is not following CDC guidelines in regards to informing employees of workers who have tested positive for Covid-19. An employee tested positive and the coworkers were not informed.
Applicable OSHA standard(s): Section 5(a)(1) General Duty Clause of the Occupational Safety and Health Act of 1970
Alleged Hazards: 1, Employees Exposed: 20
Source: Osha.gov | Receipt Date: 2020-08-05 See Less
Recent Interesting Reports
Company name: Jacobus Pharmaceutical Company Inc.
Brand name: Ruzurgi®
Product recalled: Ruzurgi® (amifampridine) 10 mg tablets
Reason of the recall: Exceeds Specification for Total Yeast and Mold Counts
FDA Recall date: September 13, 2021
Recall details: Plainsboro, New Jersey, Jacobus Pharmaceutical Company Inc. is voluntarily recalling 3... See More lots of Ruzurgi® (amifampridine) 10 mg tablets to the consumer level. The products have been found to be contaminated with yeast, mold, and aerobic bacteria based on laboratory test results.
Oral products heavily contaminated with yeast, mold, and aerobic bacteria may result in serious and life-threatening infections. The use of the defective product in patients with underlying immunosuppressive conditions such as Lambert Eaton Syndrome (LEMS) increases the concern for serious infections.
The product is used as a treatment for LEMS in patients ages 6 to less than 17 and is packaged in 100 count bottles (NDC: 49938-110-01). The affected Ruzurgi® (amifampridine) tablets lots include the following control numbers and expiration dates:
- Control Number 18038, Expiration 03/2023
- Control Number 18039, Expiration 03/2023
- Control Number 18079, Expiration 05/2023
The Control Number is located to the right of the bottle’s front panel below the D2 Barcode. Ruzurgi® (amifampridine) was distributed worldwide to specialty pharmacies and physicians.
Jacobus was informed of this issue by their Canadian partner that was conducting confirmatory full testing on Control Number 18038. Jacobus conducted an expanded investigation which identified Control Numbers 18039 and 18079.
- Control Number 18038 was distributed between 05/25/2021 – 08/26/2021 (Canada only)
- Control Number 18039 was distributed between 06/01/2021 – 08/10/2021
- Control Number 18079 was distributed between 08/10/2021 – 08/30/2021
Jacobus Pharmaceutical Company Inc is notifying its distributors and customers via regular mail and electronic mail and is arranging for the return of all recalled products.
Consumers that have Ruzurgi® (amifampridine) which is being recalled should stop using and return this product. Consumers with questions regarding this recall can contact Jacobus Pharmaceutical Company Inc. by phone at (609)799-8221 ext. 2120, Monday thru Friday from 9:00 AM to 5:00 PM Eastern Standard Time. This recall is being conducted with the knowledge of the U.S. Food and Drug Administration and other health authorities.
Check the full recall details on fda.gov
Source: FDA See Less
A boiled water advisory surrounds our street while at the same time we experience very low water pressure especially on higher floors. See Less
Company name: Teligent Pharma, Inc.
Brand name: Teligent
Product recalled: Lidocaine HCl Topical Solution 4%
Reason of the recall: Super potency
FDA Recall date: August 30, 2021
Recall details: Teligent Pharma, Inc. is voluntarily recalling one lot of Lidocaine HCl Topical Solution 4%, 50ml in a screw... See More cap glass bottle to the user level. The product is being recalled because the firms testing has found it to be super potent based on an Out of Specification (OOS) result obtained at the 18-month stability timepoint.
Risk Statement: Use of the super potent product would result in a higher than intended lidocaine dose above that intended. An increased lidocaine dose could lead to the development of local anesthetic systemic toxicity depending on the duration of the treatment and the specific patient. Local anesthetic systemic toxicity can result in central nervous system reactions including excitation and/or depression and more serious signs of cardiovascular toxicity, such as bradycardia, hypotension, and even cardiovascular collapse can present very quickly.
If local anesthetic systemic toxicity is not recognized and treated quickly, severe morbidity and even death can result. Adults and the elderly who are more likely to use this product as well as children of lower body weight are more likely to experience local anesthetic systemic toxicity if a higher than intended lidocaine concentration is administered.
To date, Teligent Pharma, Inc. has not received any reports of adverse events related to this recall. The product is indicated for the production of topical anesthesia of accessible mucous membranes of the oral and nasal cavities and proximal portions of the digestive tract and is packaged in a 50ml glass bottle with a screw cap with the identification NDC# 52565-009-50. The affected Lidocaine HCl Topical Solution 4% lot number and expiration date are: Lot # 14218, Exp. 09/2022. The product can be identified by the following labeling: Lidocaine Hydrochloride Topical Solution USP 4% (40 mg/mL).
Product was distributed at the wholesale and retail distribution levels in the US and Canada. Teligent Pharma, Inc. is notifying its distributors via Fed-Ex and is arranging for return of all recalled products. Distributors, consumers, and patients that have Lidocaine HCl Topical Solution 4% which is being recalled should return product to their place of purchase.
Consumers with questions regarding this recall can contact Teligent Pharma, Inc. by phone at 1-856-697-1441 press * to reach the medical information call center Monday through Friday, 8am – 5pm. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to taking or using this drug product.
Check the full recall details on fda.gov
Source: FDA See Less
Company name: Azurity Pharmaceuticals, Inc.
Brand name: Azurity
Product recalled: Firvanq
Reason of the recall: Product kit may contain incorrect diluent.
FDA Recall date: September 08, 2021
Recall details: Wilmington, MA, Azurity Pharmaceuticals, Inc. (“Azurity”) is voluntarily recalling one lot of Firvanq® (vancomycin hydrochloride for oral solution),... See More Vancomycin 50 mg/mL Kit (“Firvanq®”) to the consumer level, as some products in the affected lot have been found to incorrectly contain a First Omeprazole (FIRST-PPI) diluent instead of the Firvanq diluent bottle. To date, Azurity has not received any reports of adverse events related to this recall.
Risk Statement: Vancomycin may not be completely solubilized in the FIRST-PPI diluent which could lead to doses above or below those recommended in the label. There is reasonable probability that the administration of inappropriate doses of oral vancomycin may lead to persistent diarrhea associated with dehydration and electrolyte abnormalities, recurrence of Clostridium difficile (C. difficile) infection, its progression to severe colitis, colon perforation requiring colectomy, and potentially death. Especially, the elderly and immunocompromised patients are vulnerable to the complications of C. difficile infection.
Firvanq® is indicated for use in adults and pediatric patients less than 18 years of age for the treatment of: Clostridium difficile-associated diarrhea and Enterocolitis caused by Staphylococcus aureus (including methicillin-resistant strains).
The recalled product is packaged as a kit consisting of a bottle with Vancomycin Hydrochloride, USP powder, a bottle of Grape-Flavored diluent, and Full Prescribing Information. The product NDC is 65628-206-05 and the UPC code is 3 65628 206005 1. A total of 2,751 kits of the affected Firvanq®, lot number 21035, with an expiration date of 2022-07-31 were distributed. The product can be identified by its brand name Firvanq®.
This product was distributed nationwide through wholesale distributors. Azurity is notifying its distributors and customers by direct notifications to distributors and via this press release. Azurity is arranging for return and replacement of only recalled products. Consumers, distributors, and retailers that are in possession of Firvanq® from the affected lot should immediately stop using it and return it to the place of purchase. Distributors are asked to place any affected product under quarantine and return it promptly to Azurity.
Check the full recall details on fda.gov
Source: FDA See Less
PetSmart, in cooperation with the Consumer Product Safety Commission (CPSC), announced a voluntary recall of more than 100,000 of the Top Paw® Double Diner Dog Bowl after learning of a potential risk of laceration if the gasket on the bottom of the product comes off, leaving an... See More unfinished edge. No other products are affected by this recall.
According to CPSC, PetSmart has received three reports of consumers receiving cuts and scratches after handling the bowls with the unfinished edge.
- Top Paw® Double Diner Dog Bowl. SKU: 5270098. UPC: 73725775404
The recalled product is described as a set of two elevated metal dog food bowls that sit in a metal base surrounded by a plastic gasket. The bowls were sold at the pet stores from October 2017 through June 2021.
The company advises consumers to immediately stop using the recalled product and to the nearest PetSmart for a full refund.
Source: petsmartcorporate.com See Less
Company name: ICU Medical, Inc.
Brand name: Hospira
Product recalled: Aminosyn II, 15%, An Amino Acid Injection, Sulfite
Reason of the recall: Presence of visible particulate matter
FDA Recall date: September 07, 2021
Recall details: ICU Medical, Inc. is voluntarily recalling one lot (2,112 units) of Aminosyn... See More II, 15%, An Amino Acid Injection, Sulfite Free intravenous (IV) solution to the hospital/user level due to the presence of visible particulate matter identified as fibers, hair, and proteinaceous material along with other particles.
ICU Medical became aware of this issue while inspecting retain samples as part of routine process. Administration of a drug product that contains particulate matter could result in adverse events ranging from inflammation at the site of injection to more serious events that could include the formation of a blood clot obstructing the flow of blood which could lead to end-organ damage or death.
To date, ICU Medical, Inc. has not received reports of adverse events or illnesses related to this recall. Aminosyn II, Sulfite-Free, (an amino acid injection) infused with dextrose by peripheral vein infusion is indicated as a source of nitrogen in the nutritional support of patients with adequate stores of body fat, in whom, for short periods of time, oral nutrition cannot be tolerated, is undesirable, or inadequate.
Aminosyn II can be administered peripherally with dilute (5 to 10%) dextrose solution and I.V. fat emulsion as a source of nutritional support. This form of nutritional support can help to preserve protein and reduce the breakdown of organic or inorganic materials, such as proteins, sugars, fatty acids, etc. in stress conditions where oral intake is inadequate. Aminosyn II is also indicated for central vein infusion to prevent or reverse excreting more nitrogen than is being taken in in patients where the intestinal tract, by the oral, surgical opening into the stomach for the introduction of food or surgical procedure for a feeding tube routes cannot or should not be used and gastrointestinal absorption of protein is impaired.
Product was distributed nationwide both by ICU Medical direct to customers and through medical distributors. The product is for human use only. ICU Medical acquired this product from Hospira, a Pfizer company; therefore, the affected product contains a Hospira NDC number and a Hospira label. The affected product lot, manufactured in the U.S. by ICU Medical in November 2020, is listed below:
- Aminosyn® II 15% An Amino Acid Injection, Sulfite-Free. NDC: 0409-7171-17. Catalog Number: 07171-17. Lot Number: 4989094. Expiration Date: 01-Apr-2022. Configuration: Pharmacy Bulk. Package 2-liter. Flexible. Container. Manufacture Date: November 2020. Distribution Dates: January 2021 – March 2021.
ICU Medical is notifying its distributors and customers of this recall by letter and is arranging for the return of all recalled products.
Hospitals/distributors that have a product that is being recalled should stop use/further distribution and return to the place of purchase.
Customers with questions regarding this recall can call ICU Medical at 1-844-654-7780 Monday through Friday between the hours of 8 a.m. and 5 p.m. Central time. Consumers should contact their physician or healthcare provider if they have experienced any problems that may be related to using these drug products.
Check the full recall details on fda.gov
Source: FDA See Less
Company name: Top Quality Dog Food
Brand name: Top Quality Dog Food.com
Product recalled: Beef HVM
Reason of the recall: Potential Salmonella & Listeria monocytogenes contamination
FDA Recall date: August 26, 2021
Recall details: Top Quality Dog Food of Hyattsville, MD is recalling “Beef HVM” 1-pound packages... See More due to the potential of Salmonella spp., Listeria monocytogenes. Salmonella, Listeria, can affect animals eating the product and there is risk to humans handling contaminated products, especially if they have not thoroughly washed their hands after having contact with the products or any surfaces exposed to these products. Healthy people infected with Salmonella should monitor themselves for the following symptoms: nausea, vomiting, diarrhea or bloody diarrhea, abdominal cramping, and fever. Rarely, Salmonella can result in more serious ailments, including arterial infections, endocarditis, arthritis, muscle pain, eye irritation, and urinary tract symptoms.
Pets with Salmonella infections may be lethargic and have diarrhea or bloody diarrhea, fever, and vomiting. Some pets will have only decreased appetite, fever, and abdominal pain. Infected but otherwise healthy pets can be carriers and infect other animals or humans. If your pet has consumed the recalled product and has these symptoms, please contact your veterinarian. Listeria monocytogenes can cause serious and sometimes fatal infections in young children, vulnerable or elderly people, and others with compromised immune systems. Healthy people may suffer short-term symptoms such as fever, headaches, stiffness, abdominal pain, and diarrhea. Listeria monocytogenes infections pose a serious threat to pregnant woman, as it can lead to miscarriages and stillbirths. Listeria monocytogenes infections are uncommon in pets, but they are possible. Symptoms may include mild to severe diarrhea; anorexia; fever; nervous, muscular, and respiratory signs; abortion; depression; shock; and death. Healthy people should monitor themselves and their pets for symptoms.
The recalled “Beef HVM” was distributed in DC, MD, VA, DE, PA, MA, CT, and SC and product was distributed through mail order and direct delivery from 7/27/21 to 8/2/21. The “Beef HVM” comes in a 1-pound package marked with lot #071521 on the bottom right corner of the label.
No illnesses have been reported to date in connection with the “Beef HVM” 1-pound packages in question.
The contamination was noted after a state surveillance sample revealed the presence of Salmonella, Listeria monocytogenes, in some 1-pound. packages of Beef HVM. The remaining “Beef HVM” batch in our possession has been quarantined and we have discontinued the distribution of this batch while FDA and our company continue their investigation as to the source of the contamination.
We encourage all customers who received this product to dispose of any unused product immediately. If you find the “Beef HVM” 1-pound package that shows the lot number: 071521 in your possession, we urge you to return it to the place of purchase for a full refund.
Check the full recall details on fda.gov
Source: FDA See Less
The FSAI announced the recall of unauthorized novel CBD food supplements due to the presence of unsafe levels of delta‐9‐tetrahydrocannabinol (THC) based on the European Food Safety Authority (EFSA) acute reference dose.
The recalled products are:
- Jacob Hooy, 2.75%CBD+, 10 ml, Batch number: 060977-0302, Best before... See More date: Feb-2022.
- Greenway, CBD Hemp Oil, 10 ml, Batch number: CB60001, Best before date: 10/12/2022.
- The Hemp Company, CBD Oil Original, 10 ml, Batch number: 10-10-139, Best before date: 04/2022.
FSAI requested to distributors withdraw the product from the market, and Retailers remove the products from sale. Consumers should not purchase or consume any of the implicated batches of the unauthorized novel CBD food supplements.
For more recall details check on FSAI website: fsai.ie
Source: FSAI See Less
I ordered a wood cutter, chain saw, rechargeable on 3/18/21. The linked showed up on Facebook. I did not receive my chain saw. Apparently the company, Amphitrite Technology Limited has been scamming people all year. It wasn’t until I found your website that I realized I had... See More been sent this weird chain, hand cutter. There are many pictures posted on your site of the same product. I had no idea why this thing came to me. I did not think it was a “replacement” or substitute for the little chain saw that was rechargeable.
I can see there are several posts about the same problem. What can be done? Why has PayPal continued to allow the seller to sell? What can you do? What can I do, to stop others from the company”s fraud?
I purchased through PayPal; directly after this purchase my bank notified me that someone tried to buy a cell phone. What happens next? With so many reports of fraud, why hasn’t the seller been reported to officials? What can you do? What can I do on my part? I contacted PayPal. The company should be blocked from selling See Less
2da dose of Vacuna Pfizer, Colegio Municipal Sebastián de Benalcazar, Avenida 6 de Diciembre, Quito, Ecuador
3 weeks ago
I was given the second dose of the vaccine and everything was very fast in the Benalcazar, there was practically no one and a side effect I only had a little pain in my arm for a day and a half | Symptoms: Soreness See Less
#featuredcovid-19vaccinereports
#pfizer
#pfizercovid-19vaccine
#covid-19vaccine
#avenida6dediciembre
#quito
#pichincha
#ecuador
#soreness
